Original paper

Cancer Causes & Control

, Volume 23, Issue 7, pp 1099-1111

First online:

Statin use and risk of pancreatic cancer: a meta-analysis

  • Xiaobing CuiAffiliated withGuangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University
  • , Yue XieAffiliated withGuangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University
  • , Min ChenAffiliated withGuangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University
  • , Jun LiAffiliated withDepartment of Joint Surgery, Nanfang Hospital, Southern Medical University
  • , Xiaoming LiaoAffiliated withDepartment of Hepatobiliary Surgery, Nanfang Hospital, Southern Medical University
  • , Jian ShenAffiliated withDepartment of Cardiology, Zhujiang Hospital, Southern Medical University
  • , Meng ShiAffiliated withGuangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University
  • , Wenjing LiAffiliated withGuangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University
  • , Haoxuan ZhengAffiliated withGuangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University
    • , Bo JiangAffiliated withGuangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Purpose

Statins are commonly prescribed medications that potently reduce cholesterol levels and the risk of cardiovascular events. Preclinical studies suggested statins also possess cancer chemopreventive properties. However, the clinical studies provided contradictory results as to whether statins influence the risk of pancreatic cancer. Herein, we present this meta-analysis to assess the association between statin use and risk of pancreatic cancer.

Methods

We conducted a comprehensive search up to August 2011 for the eligible studies. Pooled relative risk (RR) estimates and corresponding 95 % confidence intervals (CIs) were calculated using the inverse-variance-weighted random-effects model. Subgroup analyses were conducted where data were available. Heterogeneity was assessed by the Cochran’s Q test and the I 2 statistic.

Results

We included 16 studies that involving 1,692,863 participants and 7,807 pancreatic cancer cases. Pooled results only indicated a non-significant decrease of pancreatic cancer risk among all statin users (RR 0.89; 95 % CIs, 0.74–1.07). Similar results were obtained in the subgroup analyses of the long-term (more than 4 years) follow-up (RR 0.94, 0.81–1.08) and statin use (RR 0.97, 0.76–1.23), and a null association was found between lipophilic statin use and pancreatic cancer risk (RR 1.03, 0.92–1.16). No evidence of publication bias was observed in the present meta-analysis. However, significant heterogeneity was detected among all studies (p < 0.00001, I 2 = 81 %).

Conclusions

In conclusion, our results suggest that there is no association between statin use and pancreatic cancer risk, when statins are taken at daily doses for cardiovascular event prevention.

Keywords

Statin Pancreatic cancer Risk Prevention Meta-analysis